Atrash, Shebli
Flahavan, Evelyn M.
Xu, Tao
Ma, Esprit
Karve, Sudeep
Hong, Wan-Jen
Jirau-Lucca, Gilbert
Nixon, Michael
Ailawadhi, Sikander http://orcid.org/0000-0002-8377-8111
Funding for this research was provided by:
F. Hoffmann-La Roche Ltd This is not for the individual author, but the manuscript overall
Article History
Received: 27 October 2021
Revised: 8 February 2022
Accepted: 10 February 2022
First Online: 23 March 2022
Competing interests
: SA: employment (Levine Cancer Institute, Atrium Health), research funding (Amgen, GSK, Karyopharm), honoraria (Takeda, Amgen, Karyopharm, BMS, Sanofi, Cellectar, Janssen, Celgene), speaker’s bureau (BMS, Janssen Oncology, Sanofi); EMF: employment (Roche Products Limited), equity (F. Hoffmann-La Roche Ltd); TX: employment and equity (F. Hoffmann-La Roche Ltd), previous employment (Roche Diagnostics GmbH); EM: employment and equity (Genentech, Inc.); SK: employment and equity (AbbVie); W-JH: previous employment (Genentech, Inc./F. Hoffmann-La Roche Ltd), equity (F. Hoffmann-La Roche Ltd), new affiliation (Imago BioSciences, Inc.); GJ-L: employment (Genentech, Inc.), equity (BMS, AbbVie), divested equity (Celgene); MN: employment and equity (Genentech, Inc./F. Hoffmann-La Roche Ltd); SA: research funding to the institution (Pharmacyclics, Cellectar, Amgen, Janssen, BMS, Medimmune, Phosplatin), honoraria (Takeda, Celgene).